Octave Bioscience
PrivateLast Round
Debt
Sep 4, 2025
Total Funding Raised
$139.6M
Company Overview
Octave is a healthcare technology company that develops a clinical platform to generate, analyze, and integrate data for advancing care in multiple sclerosis and other neurodegenerative diseases while optimizing medication use and reducing overall healthcare costs.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Octave Bioscience Comps
Public and private peers based on sector, stage, and business model.
Octave Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Sep 4, 2025 | ||||
| Series C | Sep 4, 2025 | ||||
| Grant | Nov 15, 2023 | ||||
| Series B Extension | Jul 26, 2023 | ||||
| Series B | Dec 17, 2020 | ||||
Series A | Jul 12, 2018 |
Key People
Founding team and executive leadership
Octave Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B Extension, Series C, Series A, Series B |
| Deerfield Management | Series B Extension, Series B |
| Silicon Valley Bank, a Division of First Citizens Bank | Debt |
| Blue Cross Blue Shield Association | Series B, Series A |
| Valhalla Foundation | Series C |
| Merck Global Health Innovation Fund | Series B Extension, Series C |
| Intermountain Ventures | Series B Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
Kirk Stockwood appointed as new Senior Vice President, Commercial.
- Oct 3, 2025
Company holds a CAP Accredited Laboratory.
Octave Bioscience Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Octave Bioscience's valuation, stock price, and market status.
